surmount-4 tirzepatide withdrawal weight regain after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial SURMOUNT-3 study design This is

Tolerability Issues : The adverse events with the GLP-1-based therapies are primarily gastrointestinal and include nausea, vomiting, constipation, or diarrhea [82], leading to meaningful discontinuation rates that limit real-world effectiveness

If youre interested in GLP-1 class therapies that are currently approved and available semaglutide and tirzepatide those are accessible through licensed telehealth providers with proper medical supervision

HUBERMAN: Welcome to the Huberman Lab podcast, where we discuss science and science-based tools for everyday life

Retrieved from Barrea, L., Vetrani, C., Verde, L., et al

Notify your doctor if you experience persistent or severe gastrointestinal issues, as dose adjustment or discontinuation may be necessary

The SURMOUNT-4 trial found that patients who continued tirzepatide 15 mg lost an additional 5.5% of body weight over 52 weeks, while those switched to placebo regained approximately 14.0% (Aronne et al., JAMA 2024)